16 completed, 1 unknown, 1 withdrawn. 10 Phase 3, 4 Phase 2, 2 Phase 1, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 10 | Completed 10 |
| Phase 2 | 4 | Completed 3, Unknown 1 |
| Phase 1 | 2 | Completed 1, Unknown 1 |
| Phase 4 | 1 | Completed 1 |
Follow Moderate to Severe Chronic Plaque Psoriasis: new trials by email Literature Review of Moderate to Severe Chronic Plaque Psoriasis trials Research Report on Moderate to Severe Chronic Plaque Psoriasis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| This is Comparative Study in Normal Healthy Subjects to Evaluate Pharmacokinetics, Safety, Tolerability of Bmab 1200 -Autoinjector (AI) After Single Subcutaneous Injection (45 mg) in Comparison With Bmab 1200 -Prefilled Syringe (PFS). Bmab 1200 (Biosimilar Ustekinumab) - Moderate to Severe Chronic Plaque Psoriasis | Phase 1 | Completed | Biocon Biologics UK Ltd | 186 | 2025-01-09 | 2025-08-19 |
| Efficacy and Safety of Infliximab Biosimilar in Treatment of Moderate to Severe Psoriasis; A Single-arm Clinical Trial Infliximab-dyyb Biosimilar (Remsima) - Moderate to Severe Chronic Plaque Psoriasis | Phase 1 / Phase 2 | Unknown | Services Institute of Medical Sciences, Pakistan | 104 | 2023-11-06 | 2024-09-19 |
| A Study to Evaluate the Efficacy and Safety of Bimekizumab in Chinese Adult Study Participants With Moderate to Severe Plaque Psoriasis Placebo, Bimekizumab - Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis | Phase 3 | Completed | UCB Biopharma SRL | 133 | 2023-10-31 | 2026-11-18 |
| A Clinical Study to Evaluate the Efficacy and Safety of Subcutaneous JS005 Injection in the Treatment of Adults With Moderate to Severe Chronic Plaque Psoriasis JS005 (recombinant humanized monoclonal antibody against IL-17A) - Moderate to Severe Chronic Plaque Psoriasis | Phase 3 | Completed | Shanghai Junshi Bioscience Co., Ltd. | 747 | 2023-08-28 | 2025-12-16 |
| To Compare Pharmacokinetics, Efficacy, and Safety of CT-P17 With Humira in Patients With Moderate to Severe Chronic Plaque Psoriasis CT-P17, EU-approved Humira - Moderate to Severe Chronic Plaque Psoriasis | Phase 3 | Completed | Celltrion | 367 | 2022-11-07 | 2024-08-21 |
| A Real-world Study to Assess Safety and Effectiveness of Secukinumab in Pediatric Plaque Psoriasis Patients in China Cosentyx - Moderate to Severe Chronic Plaque Psoriasis | Completed | Novartis Pharmaceuticals | 42 | 2022-09-08 | 2025-12-29 | |
| Comparing Efficacy and Safety of Bmab 1200 and Stelara in Patients With Moderate to Severe Chronic Plaque Psoriasis Stelara, Bmab1200 - Moderate to Severe Chronic Plaque Psoriasis | Phase 3 | Completed | Biocon Biologics UK Ltd | 384 | 2022-06-28 | 2025-09-12 |
| Efficacy, Safety, and Immunogenicity of Subcutaneous DMB-3115 Versus Stelara® in Patients With Moderate to Severe Chronic Plaque Psoriasis DMB-3115, Stelara - Moderate to Severe Chronic Plaque Psoriasis | Phase 3 | Completed | Dong-A ST Co., Ltd. | 598 | 2021-04-28 | 2024-01-18 |
| A Study to Evaluate the Safe and Effective Use of the Prefilled Safety Syringe or the Auto-injector for the Subcutaneous Self-injection of Bimekizumab Solution by Subjects With Moderate to Severe Chronic Plaque Psoriasis (PSO) Bimekizumab - Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis | Phase 3 | Completed | UCB Biopharma SRL | 172 | 2018-12-20 | 2025-07-14 |
| A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis Bimekizumab - Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis | Phase 3 | Completed | UCB Biopharma SRL | 1353 | 2018-09-05 | 2026-04-15 |
| A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis Bimekizumab, Secukinumab, Placebo - Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis | Phase 3 | Completed | UCB Biopharma SRL | 743 | 2018-06-13 | 2026-04-15 |
| A Study With a Initial Treatment Period Followed by a Randomized-withdrawal Period to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis Bimekizumab, Placebo - Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis | Phase 3 | Completed | UCB Biopharma SRL | 435 | 2018-02-05 | 2026-04-15 |
| A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Placebo and an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis Bimekizumab, Ustekinumab, Placebo - Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis | Phase 3 | Completed | UCB Biopharma SRL | 567 | 2017-12-06 | 2026-04-15 |
| A Study of Multiple Doses of AbGn-168H by Intravenous Infusion in Patients With Moderate to Severe Chronic Plaque Psoriasis AbGn-168H, Placebo - Moderate to Severe Chronic Plaque Psoriasis | Phase 2 | Completed | AbGenomics B.V Taiwan Branch | 50 | 2014-05-01 | 2016-04-14 |
| Phase IIa Study of Multiple Doses of AbGn-168H by iv Infusion in Moderate to Severe Chronic Plaque Psoriasis Patients AbGn-168H, placebo - Moderate to Severe Chronic Plaque Psoriasis | Phase 2 | Completed | AbGenomics B.V Taiwan Branch | 54 | 2013-05-01 | 2015-05-08 |
| Post Marketing Observational Study on Venezuelan Patients With Psoriasis Moderate to Severe Chronic Plaque Psoriasis | Withdrawn | AbbVie (prior sponsor, Abbott) | 2013-02-01 | 2016-11-29 | ||
| A Study to Evaluate the Safety and Effectiveness of Doxercalciferol Capsules in Participants With Moderate to Severe Psoriasis Doxercalciferol, Placebo - Moderate to Severe Chronic Plaque Psoriasis | Phase 2 | Completed | Genzyme, a Sanofi Company | 111 | 2008-04-01 | 2014-05-05 |
| Community Based Trial for AMEVIVE® Alefacept - Moderate to Severe Chronic Plaque Psoriasis | Phase 4 | Completed | Astellas Pharma Inc | 114 | 2004-07-01 | 2014-09-08 |
Psoriasis (10) · Arthritis, Psoriatic (2)
Skin Diseases (10) · Skin Diseases, Papulosquamous (10) · Skin and Connective Tissue Diseases (10) · Arthritis (2) · Bone Diseases (2) · Joint Diseases (2) · Musculoskeletal Diseases (2) · Spinal Diseases (2) · Spondylarthritis (2) · Spondylarthropathies (2) · Spondylitis (2)
bimekizumab (6) · Ustekinumab (3) · secukinumab (2) · 1 alpha-hydroxyergocalciferol (1) · Alefacept (1) · CT-P13 (1) · CT-P17 (1)
UCB Biopharma SRL (6) · AbGenomics B.V Taiwan Branch (2) · Biocon Biologics UK Ltd (2) · AbbVie (prior sponsor, Abbott) (1) · Astellas Pharma Inc (1) · Celltrion (1) · Dong-A ST Co., Ltd. (1) · Genzyme, a Sanofi Company (1) · Novartis Pharmaceuticals (1) · Services Institute of Medical Sciences, Pakistan (1) · Shanghai Junshi Bioscience Co., Ltd. (1)
United States (11) · Canada (5) · Australia (4) · Germany (4) · Poland (4) · United Kingdom (4) · Belgium (3) · China (3) · Hungary (3) · Russia (3) · Italy (2) · Japan (2) · South Korea (2) · Estonia (1) · France (1)
Mark Lebwohl, MD (2) · Dr Hira Tariq, MBBS, FCPS Derma (1) · Michael Gold (1) · Natali Serra-Bonett, MD (1) · Shih-Yao Lin, MD, Ph.D (1) · Shih-Yao Lin, MD, PhD (1)
PMID 39578348, PMID 41060492, PMID 41800601, PMID 35544084, PMID 36751950, PMID 37950894, PMID 40286813, PMID 40886218, PMID 41359217, PMID 41580158, PMID 34260044, PMID 38588819, PMID 33549192, PMID 33549193, PMID 33891380, PMID 34001692, PMID 34471992, PMID 35133113, PMID 36648594, PMID 36689515, PMID 37182701, PMID 39285121, PMID 39862230, PMID 39932677, PMID 40148673, PMID 40156698, PMID 40708530, PMID 40788331, PMID 41100115, PMID 41678327, PMID 41706476, PMID 42643157
2016 (3), 2017 (1)